Success Metrics

Clinical Success Rate
100.0%

Based on 4 completed trials

Completion Rate
100%(4/4)
Active Trials
0(0%)
Results Posted
50%(2 trials)

Phase Distribution

Ph phase_3
3
75%

Phase Distribution

0

Early Stage

0

Mid Stage

3

Late Stage

Phase Distribution3 total trials
Phase 3Large-scale testing
3(100.0%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

100.0%

4 of 4 finished

Non-Completion Rate

0.0%

0 ended early

Currently Active

0

trials recruiting

Total Trials

4

all time

Status Distribution
Completed(4)

Detailed Status

Completed4

Development Timeline

Analytics

Development Status

Total Trials
4
Active
0
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 33 (100.0%)

Trials by Status

completed4100%

Recent Activity

0 active trials
Showing 4 of 4
completed

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

NCT03249506
completedphase_3

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

NCT00396227
completedphase_3

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

NCT00975286
completedphase_3

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

NCT01468181

Clinical Trials (4)

Showing 4 of 4 trials
NCT03249506

Cardiovascular Outcomes in Participants With Type 2 Diabetes Mellitus (T2DM)

Completed
NCT00396227Phase 3

Safety and Efficacy of Vildagliptin vs. Thiazolidinedione as add-on Therapy to Metformin in Patients With Type 2 Diabetes Not Controlled With Metformin Alone

Completed
NCT00975286Phase 3

24-week Treatment With Lixisenatide in Type 2 Diabetes Insufficiently Controlled With Metformin and Insulin Glargine

Completed
NCT01468181Phase 3

A Study of LY2189265 in Japanese Participants With Type 2 Diabetes Mellitus

Completed

All 4 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
4